ALLO
Allogene Therapeutics Inc

3,393
Mkt Cap
$585.07M
Volume
1,854.00
52W High
$2.80
52W Low
$0.8621
PE Ratio
-2.76
ALLO Fundamentals
Price
$2.44
Prev Close
$2.40
Open
$2.40
50D MA
$1.92
Beta
1.59
Avg. Volume
5.97M
EPS (Annual)
-$0.8652
P/B
1.88
Rev/Employee
$0.00
$135.30
Loading...
Loading...
News
all
press releases
Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Expands By 19.8%
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) was the recipient of a large increase in short interest in February. As of February 27th, there was short interest totaling 23,927,216...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Canaccord Genuity Group Reiterates Buy Rating for Allogene Therapeutics (NASDAQ:ALLO)
Canaccord Genuity Group reissued a "buy" rating and issued a $14.00 price objective on shares of Allogene Therapeutics in a research note on Friday...
MarketBeat·4d ago
News Placeholder
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Expected to Rise, Piper Sandler Analyst Says
Piper Sandler raised their price target on Allogene Therapeutics from $7.00 to $8.00 and gave the company an "overweight" rating in a report on Friday...
MarketBeat·4d ago
News Placeholder
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4
ALLO posts a narrower Q4 loss than expected, cuts expenses and advances key CAR-T studies, with cash projected to fund operations into 2028.
Zacks·4d ago
News Placeholder
Allogene Therapeutics Q4 Earnings Call Highlights
Allogene Therapeutics (NASDAQ:ALLO) used its fourth-quarter 2025 conference call to outline what management described as a defining year ahead, with multiple clinical catalysts expected in 2026 and...
MarketBeat·5d ago
News Placeholder
Allogene Therapeutics (NASDAQ:ALLO) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS
Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) announced its earnings results on Thursday. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by...
MarketBeat·5d ago
News Placeholder
Allogene Therapeutics (NASDAQ:ALLO) Shares Up 7.4% - Here's Why
Allogene Therapeutics (NASDAQ:ALLO) Trading Up 7.4% - Here's Why...
MarketBeat·8d ago
News Placeholder
Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus
ALLO, SBUX and AMGN highlight how Zacks strategies and portfolio picks are delivering strong gains despite recent market volatility.
Zacks·8d ago
News Placeholder
Benjamin Machinas Beneski Sells 7,132 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Benjamin Machinas Beneski sold 7,132 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price...
MarketBeat·12d ago
News Placeholder
Allogene Therapeutics (ALLO) Expected to Announce Earnings on Thursday
Allogene Therapeutics (NASDAQ:ALLO) will be releasing its Q4 2025 earnings after the market closes on Thursday, March 12. (View Earnings Report at...
MarketBeat·12d ago
<
1
2
...
>

Latest ALLO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.